Supporting All Stakeholders
FACT: Multiple clinical trials for treatments specific to Fragile X syndrome have failed, leaving the community searching for treatments to improve quality of life in FXS.
FACT: Clinical trials take an average of 11 years and $2.6 billion to bring a drug to market.
We want to leverage participants’ contributions in clinical trials and make the de-identified data widely available to the Fragile X research community to expedite treatment development. This is part of the NFXF’s effort to support all stakeholders — Fragile X professionals, families, and researchers — to be engaged in the process to promote better outcomes for families living with Fragile X.
Our Role as Steward
There is a growing trend of patient advocacy organizations becoming more actively involved in data stewardship. Given our status as the leading patient advocacy organization for Fragile X, and our experience with collecting data in partnership with the FXCRC clinics and the CDC for the FORWARD registry and database, the NFXF is the best equipped to centralize all de-identified clinical trial data for future research. The NFXF can provide unbiased access to all reputable projects wanting to utilize these data, while at the same time ensuring that all data remains de-identified for maximal patient safety and confidentiality.
NFXF is the best equipped to centralize all de-identified clinical trial data for future research.
Our efforts to advance treatment research ensures that valuable clinical and biological data from clinical trials can live on beyond the initial trials, furthering the investment of time and resources for families and researchers, and ultimately supporting new treatment research.
A Readily Available, Inclusive Repository
The NFXF Data Repository™ is an inclusive repository of all valuable data, including NFXF survey data and NFXF Biobank data. The Data Repository allows research data to be readily available to the broader community for future research.
- Leveraging patient data from previous trials will enable new trialists to complete their proof-of-concept work without having to recruit participants and collect samples.
- Leveraging survey data from prior NFXF work enables development of better outcome measures and serves as a jumping off point for collaborative conversations to better research in Fragile X.
This is important because we know that there are many important things that lead to advancing treatment research. Having data living on past its initial collection is best for families and cost effective for researchers. Both clinical and biological data are valuable, and the Data Repository captures the importance of both. We have multiple sources contributing data, including our NFXF Biobank pilot project, the STX209 Reconsent project, and data rollover from future trials. The paired clinical and biological de-identified data in the Data Repository will allow researchers to jumpstart projects in meaningful ways, including treatment development.
Biomarkers are a big piece of the researcher puzzle, and so are better outcome measures specific to Fragile X and better representation in research so that treatments are effective for any individual living with Fragile X. The NFXF Data Repository allows us to look at research from these angles, doing parallel work in impactful areas. Including qualitative data in the NFXF Data Repository helps us examine additional angles.
The Data Repository includes qualitative survey data, like the Voice of the Person and Anxiety Survey (available next year) data, that can contribute to additional meaningful work to advance treatment research.
We know we need better outcome measures in FX. NFXF plans to start this collaborative conversation with industry and academic researchers by utilizing the survey data in the NFXF Data Repository. Understanding how self-advocates, parents, and caregivers perceive and rate the symptoms of Fragile X is important in developing a measurement that can accurately capture baseline symptomology and change.